Zeev Bronfeld insider trades: Protalix BioTherapeutics (PLX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Zeev reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 13, 2014 | PLX | ↓ Sell | 4,400,000 | $2.47 | $10.9M | By Trust | Aug 15, 2014 (2d) |
| Sep 27, 2011 | ORMP.OB | ↓ Sell | 350,000 | $0.28 | $98K | Direct | Sep 28, 2011 (1d) |
| Mar 31, 2011 | ORMP.OB | ↑ Buy | 781,250 | $0.32 | $250K | Via DNA Biomedical Solutions Ltd. | Apr 4, 2011 (4d) |
| Apr 30, 2007 | GEYI | ↑ Buy | 30,000,000 | $0.01 | $300K | Carrigain Investment Ltd. | May 4, 2007 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PLX insiders
Open-market trades in the last 12 months
About Zeev Bronfeld's insider trades
Zeev Bronfeld is a director at Protalix BioTherapeutics (PLX). Since Apr 30, 2007, Zeev has reported 2 open-market purchases worth $550K and 2 sales worth $11.0M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (3 filings), other transactions (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PLX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.